Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk

International Journal of Molecular Sciences

Volumn 13, Issue 4, 2012, Pages 4009-4020

  Zhang, Li ^a   Liu, Wenxin ^a   Hao, Quan ^a   Bao, Lewen ^a   Wang, Ke ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Folate; Methylenetetrahydrofolate reductase gene; Ovarian cancer risk; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; FOLIC ACID; FLUOROURACIL; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DEATH; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MTHFR GENE; OVARY CANCER; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; VITAMIN INTAKE; COHORT ANALYSIS; DIET SUPPLEMENTATION; EATING; FEEDING BEHAVIOR; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; QUESTIONNAIRE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; COHORT STUDIES; DIETARY SUPPLEMENTS; EATING; FEMALE; FLUOROURACIL; FOLIC ACID; FOOD HABITS; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84860186318     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13044009     Document Type: Article

References (33)

1. Kristensen, G.B.; Trope, C. Epithelial ovarian carcinoma. Lancet 1997, 349, 113-117.
2. Jin, F.; Shu, X.O.; Devesa, S.S.; Zheng, W.; Blot, W.J.; Gao, Y.T. Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-89. Cancer Causes Control. 1993, 4, 355-360.
3. La Vecchia C. Epidemiology of ovarian cancer: A summary review. Eur. J. Cancer Prev. 2001, 10, 125-129.
4. Zhang, M.; Xie, X.; Lee, A.H.; Binns, C.W. Soy and isoflavone intake are associated with reduced risk of ovarian cancer in southeast China. Nutr. Cancer 2004, 49, 125-130.
5. Aune, D.; Deneo-Pellegrini, H.; Ronco, A.L.; Boffetta, P.; Acosta, G.; Mendilaharsu, M.; de Stefani E. Dietary folate intake and the risk of 11 types of cancer: A case-control study in Uruguay. Ann. Oncol. 2010, 22, 444-451.
6. Kim, Y.I. Will mandatory folic acid fortification prevent or promote cancer? Am. J. Clin. Nutr. 2004, 80, 1123-1128.
7. Larsson, S.C.; Giovannucci, E.; Wolk, A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: A meta-analysis. Gastroenterology 2006, 131, 1271-1283.
8. Choi, S.W.; Mason, J.B. Folate and carcinogenesis: An integrated scheme. J. Nutr. 2000, 13, 129-132.
9. Gallus, S.; La Vecchia, C. Is there a link between diet and esophageal cancer? Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 2-3.
10. Blount, B.C.; Mack, M.M.; Wehr, C.M.; MacGregor, J.T.; Hiatt, R.A.; Wang, G. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc. Natl. Acad. Sci. USA 2007, 94, 3290-3295.
11. Bailey, L.B.; Gregory, J.F., 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J. Nutr. 1999, 129, 919-922.
12. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P.; et al. A candidate genetic risk factor for vascular disease: A commonmutation inmethylenetetrahydrofolate reductase. Nat. Genet. 1995, 10, 111-113.
13. Terry, K.L.; Tworoger, S.S.; Goode, E.L.; Gates, M.A.; Titus-Ernstoff, L.; Kelemen, L.E.; Sellers, T.A.; Hankinson, S.E.; Cramer, D.W. MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol. Oncol. 2010, 119, 319-324.
14. Upadhyay, R.; Jain, M.; Kumar, S.; Ghoshal, U.C.; Mittal, B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat. Res. 2009, 663, 52-59.
15. Upadhyay, R.; Jain, M.; Kumar, S.; Ghoshal, U.C.; Mittal, B. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: An exploratory study. Clin. Immunol. 2008, 128, 199-204.
16. Jain, M.; Tilak, A.R.; Upadhyay, R.; Kumar, A.; Mittal, B. Microsomal epoxide hydrolase (EPHX1), slow (exon 3, 113His) and fast (exon 4, 139Arg) alleles confer susceptibility to squamous cell esophageal cancer. Toxicol. Appl. Pharmacol. 2008, 230, 247-251.
17. Wang, J.; Sasco, A.J.; Fu, C.; Xue, H.; Guo, G.; Hua, Z.; Zhou, Q.; Jiang, Q.; Xu, B. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev. 2008, 17, 118-125.
18. Mason, J.B. Folate, cancer risk, and the Greek god, Proteus: A tale of two chameleons. Nutr. Rev. 2009, 67, 206-212.
19. Webb, P.M.; Ibiebele, T.I.; Hughes, M.C.; Beesley, J.; van der Pols, J.C.; Chen, X.; Nagle, CM.; Bain, C.J.; Chenevix-Trench, G. Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group.Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. Eur. J. Clin. Nutr. 2011, 65, 1133-1140.
20. Harris, H.R.; Cramer, D.W.; Vitonis, A.F.; Depari, M.; Terry, K.L. Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int. J. Cancer 2011, 22, doi:10.1002/ijc.26455.
21. Ito, H.; Shinoda, M.; Hatooka, S.; Hirose, K.; Wakai, K.; Saito, T.; Wakai, K.; Saito, T.; Suzuki, T.; Maeda, T.; et al. Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: Results of a case-control study in Japan. Carcinogenesis 2005, 26, 1285-1290.
22. Wang, Y.; Guo, W.; He, Y.; Chen, Z.; Wen, D.; Zhang, X.; Wang, N.; Li, Y.; Ge, H.; Zhang, J. Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control 2007, 18, 143-152.
23. Goode, E.L.; Maurer, M.J.; Sellers, T.A.; Phelan, C.M.; Kalli, K.R.; Fridley, B.L.; Vierkant, R.A.; Armasu, S.M.; White, K.L.; Keeney, G.L.; et al. Inherited determinants of ovarian cancer survival. Clin. Cancer Res. 2010, 16, 995-1007.
24. Jakubowska, A.; Gronwald, J.; Menkiszak, J.; Górski, B.; Huzarski, T.; Byrski, T.; Edler, L.; Lubiński, J.; Scott, R.J.; Hamann, U. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res. Treat. 2007, 104, 299-308.
25. Zhang, Z.G.; Rustum, Y.M. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: Biochemical mechanisms. Semin. Oncol. 1992, 19, 46-50.
26. Carlsson, G.; Hafström, L.O.; Spears, C.P.; Gustavsson, B.; Larsson, P.A. 5-fluorouracil (5-FU) and 5, 10-methylene tetrahydrofolate (5, 10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model. Anticancer Res. 1997, 17, 3671-3674.
27. Cohen, V.; Panet-Raymond, V.; Sabbaghian, N.; Morin, I.; Batist, G.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidinebased chemotherapy. Clin. Cancer Res. 2003, 9, 1611-1615.
28. Lu, C.; Xie, H.; Wang, F.L.; Shen, H.B.; Wang, J.M. Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association in the prognosis of esophageal squamous cell carcinoma. BMC Cancer 2011, 11, doi:10.1186/1471-2407-11-91.
29. Sarbia, M.; Stahl, M.; von Weyhern, C.; Weirich, G.; Pühringer-Oppermann, F. The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br. J. Cancer 2006, 94, 203-207.
30. Hunn, J.; Rodriguez, G.C. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 2012, 55, 3-23.
31. Sawabe, M.; Arai, T.; Araki, A.; Hosoi, T.; Kuchiba, A.; Tanaka, N.; Naito, T.; Oda, K.; Ikeda, S.; Muramatsu, M. Smoking confers a MTHFR 677C>T genotype-dependent risk for systemic atherosclerosis: Results from a large number of elderly autopsy cases that died in a community-based general geriatric hospital. J. Atheroscler. Thromb. 2009, 16, 91-104.
32. Tsai, C.W.; Hsu, C.F.; Tsai, M.H.; Tsou, Y.A.; Hua, C.H.; Chang, W.S.; Lin, C.C.; Bau, D.T. Methylenetetrahydrofolate reductase (MTHFR) genotype, smoking habit, metastasis and oral cancer in Taiwan. Anticancer Res. 2011, 31, 2395-2399.
33. Supic, G.; Jovic, N.; Kozomara, R.; Zeljic, K.; Magic, Z. Interaction between the MTHFR C677T polymorphism and alcohol-impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J. Dent. Res. 2011, 90, 65-70.